Biogen partner Eisai completes FDA submissions for injectable Alzheimer’s therapy
Japanese drugmaker Eisai (OTCPK:ESAIY) (OTCPK:ESALF), Biogen's (NASDAQ:BIIB) partner for intravenous Alzheimer's therapy, ...
Benzinga.com7d
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
Also Read: Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial The results were shared at the American College of Rheumatology ...
Seeking Alpha8d
Biogen, UCB release phase 3 data on lupus candidate dapirolizumab
A phase 3 trial of Biogen (NASDAQ:BIIB) and UCB's (OTCPK:UCBJF)(OTCPK:UCBJY) dapirolizumab pegol for systemic lupus erythematosus met its primary endpoint, demonstrating significant improvement in ...
Bloomberg L.P.29d
Biogen Raises Forecast as Alzheimer’s Drug Leqembi Shows Signs of Growth
Biogen Raises Forecast as Alzheimer’s Drug Leqembi Shows Signs of Growth Quarterly Leqembi sales reached $67 million, beating estimates Cost cuts to drive high-teen percentage operating income boost ...
Yahoo Finance29d
Biogen Raises Forecast as Alzheimer’s Drug Leqembi Shows Signs of Growth
Last year, Biogen announced plans to cut 1,000 jobs — over 11% of its workforce — and reduce operating expenses by an additional $700 million by 2025. On Wednesday, the company projected that ...